Nationwide Children’s Hospital study identifies potential new pathway for drug development

A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children’s Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development. The study appears in PLOS ONE.

More than one-third of drugs on the market work by targeting G protein-coupled receptors that control how cells communicate and function. With many hundreds of members, G protein-coupled receptors are the largest family of signaling receptors throughout the body. Full press release here.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

Codonics honored by Frost & Sullivan for enhancing patient safety and accuracy of medication management with the Safe Label System | Frost & Sullivan, November 20, 2014

Microbial Robotics’ new genetics rights management product platform enters international markets with patent filing | PR Newswire, November 19, 2014

Matrix Medical Devices of Cleveland purchases Mentor-based REU Associates | Crains Cleveland Business, November 19, 2014

Global Emerging Pathogen Treatment Consortium formed to study potential of immune plasma treatment in the fight against Ebola, ClinicalRM, USAMRIID | PR Newswire, November 19, 2014

Freedom Meditech granted key U.S. patent covering the ClearPath DS-120 device and method of use | PR Newswire, November 19, 2014

New Ricerca CEO remains positive as questions linger over company | Outsourcing Pharma, November 19, 2014

Cleveland Clinic and Parker Hannifin developing hundreds of potential medical advancments | MedCity News, November 18, 2014

Ohio State University Comprehensive Cancer Center researcher wins supercomputing award for cancer research | Ohio Supercomputer Center, November 18, 2014

CTI Clinical Trial and Consulting Services opens office in Belgium, their sixth new location this year | Cincinnati Business Courier, November 18, 2014

Successful “Date Certain M&A” of AxioMed Spine Corp. its assets and intellectual property | Gerbsman Partners, November 18, 2014

889 Global Solutions profiled by WOSU Career Connections Series (video) | WOSU Public Media via YouTube, November 18, 2014

Duke University Hospital using technology from Dayton-area firm, Riverain Technologies | Dayton Business Journal, November 18, 2014

Ricerca Biosciences acquired by Main Market Partners, a growth-oriented equity investment group | PR Newswire, November 18, 2014

STATKING Clinical Services celebrates 25 years serving the pharmaceutical and medical device industry | BioOhio, November 18, 2014

EnzymeBioSystems announces an independent research group reported breast cancer preventive efficacy for a novel synthetic triterpenoid | PR Newswire, November 17, 2014

Summa Health System names Dr. Thomas Malone as new CEO | Cleveland.com, November 17, 2014

Invacare announces retirement of Joseph Richey, President Technologies Division, Sr VP Electronic and Design Engineering | Business Wire, November 17, 2014

Ohio doctor’s method could reduce breast cancer treatment risks, University of Toledo, ProMedica Health | Toledo Free Press, November 15, 2014

Health-care reform: Device makers squeezed by law meant to reduce costs | Columbus Business First, November 14, 2014

Cleveland Clinic spinout company Adeo LLC aims to prevent technologies from getting lost in the shuffle | Crains Cleveland Business, November 14, 2014